Immunovia AB: Immunovia announces the financial calendar for financial year 2023

2022-11-11 16:50:00

February 9, 2023 Year-end report 2022
April 25, 2023 Q1 2023
August 24, 2023 Q2 2023
November 9, 2023 Q3 2023
February 21, 2024 Year-end report 2023

The Annual General Meeting will be held on April 27, 2023.

For more information, please contact:
Karin Almqvist Liwendahl
CFO
kain.almqvist.liwendahl@immunovia.com
+46 70911 56 08

About Immunovia
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.

Our first product, IMMray™ PanCan-d is the only blood test currently available for early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups. 

The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visitwww.immunovia.com.

Cision